drugset

drugset / Trial / NCT02474017

An Open Study to Assess the Robustness of the CRC749 Inhaler

NCT02474017 ↗

Phase 1 Completed 111 enrolled Mylan Pharma UK Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To confirm the robustness of the CRC749 inhaler.

Timeline

Start: 2015-05
Primary completion: 2015-06
Completion: 2015-06

Publications

Allan R, Canham K, Wallace R, Singh D, Ward J, Cooper A, Newcomb C. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2021 Apr;34(2):134-145. doi: 10.1089/jamp.2020.1603. Epub 2020 Aug 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Fluticasone propionate	Other / unclassified	250 ug	Inhaled
Background	Salmeterol	Other / unclassified	50 ug	Inhaled

Indications